Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

2.

Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.

Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE; National Cancer Institute Phase 0 Clinical Trials Team.

Clin Cancer Res. 2008 Nov 1;14(21):6877-85. doi: 10.1158/1078-0432.CCR-08-0214.

3.

Patient perspectives on phase 0 clinical trials.

Gutierrez M, Collyar D.

Clin Cancer Res. 2008 Jun 15;14(12):3689-91. doi: 10.1158/1078-0432.CCR-07-4561. No abstract available.

4.

Designing phase 0 cancer clinical trials.

Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.

Clin Cancer Res. 2008 Jun 15;14(12):3675-82. doi: 10.1158/1078-0432.CCR-07-4560.

5.

Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH.

Mol Interv. 2007 Dec;7(6):325-34. doi: 10.1124/mi.7.6.9. Review.

PMID:
18199854
6.

Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.

Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A, Johnson DH, Colevas AD, Low J, Rothenberg ML, Lu B.

Clin Cancer Res. 2007 May 15;13(10):3033-42.

7.

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.

Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ.

Clin Cancer Res. 2007 May 1;13(9):2728-37.

8.

Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.

Ratnam K, Low JA.

Clin Cancer Res. 2007 Mar 1;13(5):1383-8. Review.

9.

Compressing drug development timelines in oncology using phase '0' trials.

Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.

Nat Rev Cancer. 2007 Feb;7(2):131-9. Review.

PMID:
17251919
10.

Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation.

Helft PR, Daugherty CK.

J Clin Oncol. 2006 Oct 20;24(30):4793-5. No abstract available.

PMID:
17050863
11.

Poly(ADP-ribose): novel functions for an old molecule.

Schreiber V, Dantzer F, Ame JC, de Murcia G.

Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28. Review.

PMID:
16829982
12.

Inhibition of poly(ADP-ribose) polymerase in cancer.

Plummer ER.

Curr Opin Pharmacol. 2006 Aug;6(4):364-8. Epub 2006 Jun 5. Review.

PMID:
16753340
13.

Chemopotentiation by PARP inhibitors in cancer therapy.

Tentori L, Graziani G.

Pharmacol Res. 2005 Jul;52(1):25-33. Review.

PMID:
15911331
14.

Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.

Jagtap P, Szabó C.

Nat Rev Drug Discov. 2005 May;4(5):421-40. Review.

PMID:
15864271
15.

Can the pharmaceutical industry reduce attrition rates?

Kola I, Landis J.

Nat Rev Drug Discov. 2004 Aug;3(8):711-5. doi: 10.1038/nrd1470. Review. No abstract available.

PMID:
15286737
16.

The PARP superfamily.

Amé JC, Spenlehauer C, de Murcia G.

Bioessays. 2004 Aug;26(8):882-93. Review.

PMID:
15273990
17.

Regulation of chromatin structure and gene activity by poly(ADP-ribose) polymerases.

Tulin A, Chinenov Y, Spradling A.

Curr Top Dev Biol. 2003;56:55-83. Review. No abstract available.

PMID:
14584726
18.

Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.

Dowlati A, Haaga J, Remick SC, Spiro TP, Gerson SL, Liu L, Berger SJ, Berger NA, Willson JK.

Clin Cancer Res. 2001 Oct;7(10):2971-6.

19.

Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma.

Shiobara M, Miyazaki M, Ito H, Togawa A, Nakajima N, Nomura F, Morinaga N, Noda M.

J Gastroenterol Hepatol. 2001 Mar;16(3):338-44.

PMID:
11339428
20.

The response of Parp knockout mice against DNA damaging agents.

Masutani M, Nozaki T, Nakamoto K, Nakagama H, Suzuki H, Kusuoka O, Tsutsumi M, Sugimura T.

Mutat Res. 2000 Apr;462(2-3):159-66.

PMID:
10767627

Supplemental Content

Support Center